News Release

05/21/2013
Event Calendar
8th International China Pharmaceutical R&D Summit
05/15/2013
Release
Acceptance of Investment from Third Party Into Beijing Continent
03/04/2013
Event Calendar
5th China & 3rd Asia Clinical Trials Outsourcing Congress
02/28/2013
Release
Patent established additional usage in Japan of F647 and F351 to cover application for Preventing Radiation-Caused Lung Injury in Japan, also in the U.S. obtained patent for pharmaceutical composition of F200
02/14/2013
Release
Announcement of the 12th Annual General Shareholder Meeting
02/04/2013
Release
Submission of Manufacturing and Distribution Permission Application regarding IPF treatment drug, F647
01/23/2013
Release
GNI Seeks New Indication for F647 (Pirfenidone)
01/16/2013
Release
Notice of Increasing the Capital of Shanghai Genomics
11/29/2012
Information
The Beijing Evening News channel visited Beijing Continent Pharmaceuticals for its pirfenidone product development program and interviewed Dr. Ying Luo.
10/30/2012
Event Calendar
G20 Innovation Award
10/17/2012
Information
F351 clinical trial for liver fibrosis
06/18/2012
Event Calendar
BIO2012
06/12/2012
Release
Patent Allowance for Pirfenidone／F647 and its Derivative's Use in Radiation-Caused Lung Injury
06/04/2012
Release
Notice of Subsidiary Company Establishment of Shanghai Genomics Inc.
04/30/2012
Information
The China Pharmaceutical & Biotechnology Review, a monthly publication covering all aspects of the industry (2012 volume 58), published a panel discussion with Dr. Ying Luo and other Experts from biotechs and research institutes in China.